Oobli
describes itself as the first and only commercial-scale sweet-protein technology platform; received its third FDA "no questions" letter in September 2025 for its brazzein-based sweetening ingredient, and announced an Andean regional manufacturing partnership in April 2026 with Magdalena,…
- Country
- United States
Coverage
| EU | US | |
|---|---|---|
| food-alt-protein | ✓ | ✓ |
Regulatorsfdaefsa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Sweet proteins (brazzein, thaumatin, monellin) | food-alt-protein | Medium | → |
Compiled by BIOECON via the bioecon-brief pipeline.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.